Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
NCT04372732
·
clinicaltrials.gov ↗
UNKNOWN
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Immunotherapy
Interventions
DIAGNOSTIC_TEST:
Serum tumor autoantibody detection
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China